Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours

Neoplasms Clinical Trial

Official title:

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01772563
• Other study ID #: 1230.24
• Secondary ID: 2011-002367-23
• Status: Completed
• Phase: Phase 1
• Start date: February 4, 2013
• Est. completion date: April 22, 2021

Study information

• Verified date: November 2022
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the present study is to investigate the influence of co-administration of itraconazole and volasertib on the pharmacokinetic profile of volasertib without co-administration of itraconazole. Secondary objectives are to investigate safety, tolerability and preliminary therapeutic effects following intravenous administration of volasertib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: April 22, 2021
• Est. primary completion date: May 30, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria:

1. Patients with histologically or cytologically confirmed diagnosis of advanced, non resectable and / or metastatic solid tumour, for whom conventional treatment has failed, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment based on the investigator's assessment

2. Male or female

3. Age =>18 and =<70 years

4. Eastern Cooperative Oncology Group (ECOG) performance score =< 2

5. Recovery from Common Terminology Criteria for Adverse Events (CTCAE) Grade >= 2 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapy (except alopecia)

Exclusion criteria:

1. Serious concomitant non-oncological disease considered by the investigator to be incompatible with the protocol

2. Active infectious disease

3. Viral hepatitis, HIV infection

4. Clinical evidence of active brain metastasis or leptomeningeal disease during the past 6 months

5. Second malignancy currently requiring active therapy (except for hormonal / antihormonal treatment e.g. in prostate or breast cancer)

6. Absolute neutrophil count less than 1,500/mm3

7. Platelet count less than 100,000/mm3

8. Total bilirubin greater than 1.5 mg/dL (> 26 µmol/L, SI unit equivalent)

9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)

10. Serum creatinine greater than 2x upper limit of normal (ULN)

11. QTcF prolongation > 470 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the mean of the 3 ECGs taken at screening

12. Female patients with childbearing potential and unwilling to use a medically acceptable method of contraception during the trial and for at least six months after end of active therapy. Woman of childbearing potential (premenopausal female) is defined as the female who is not surgically sterilised by hysterectomy or bilateral tubal ligation or post-menopausal for at least 12 months.

13. Treatment with other investigational drugs or participation in another clinical trial within the past four weeks prior to start of therapy or concomitantly with this trial

14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy within the past four weeks prior to start of therapy or concomitantly with this trial. This restriction does not apply to steroids, bisphosphonates hormonal / antihormonal treatment (e.g. in prostate or breast cancer).

15. Alcohol abuse more than an average 3 units of alcoholic beverages per day or more than 21 units per week (1 unit equals 0.5 pint [285 mL] of beer or lager, 1 glass [125 mL] of wine, 25 mL shot of 40% spirit) or drug abuse

16. Life expectancy less than 12 weeks

17. Potent CYP 3A4 and P-glycoprotein inhibitors other than the study drug or inducers between one week prior to first drug administration or expected treatment with a respective drug until the last PK sample is collected

1. Strong CYP 3A4 inhibitors: atazanavir, clarithromycin, indinavir, itraconazole (other then study drug), ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin

2. CYP 3A4 inducers: carbamazepine, rifampicin

3. P-gp inhibitors: cyclosporine, erythromycin, itraconazole (other then study drug), ketoconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil

4. P-gp inducers: hypericum perforatum, rifampicin

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• volasertib
Solution for infusion
• itraconazole
capsules

Locations

Country	Name	City	State
Hungary	National Institute of Oncology	Budapest
Hungary	PRA Hungary Ltd., Phase I. Clinical Pharmacology Unit	Budapest

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to the Last Quantifiable Drug Plasma Concentration After Dose Administration (AUC0-tz) of Volasertib and Its Metabolite CD 10899	Area under the plasma concentration-time curve over the time interval from zero to the last quantifiable drug plasma concentration after dose administration (AUC0-tz) of volasertib and its metabolite CD 10899 is reported.	30 minutes before volasertib administration and 1 hour (h), 1.75h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 168h, 336h, 504 h after volasertib administration on Day 1 of Cycle 1 (Volasertib+ Itraconazole) and of Cycle 2 (Volasertib).
Primary	Maximum Measured Concentration of Volasertib and Its Metabolite CD 10899 in Plasma (Cmax)	Maximum measured concentration of the analyte (volasertib and its metabolite CD 10899) in plasma (Cmax) is reported.	30 minutes before volasertib administration and 1 hour (h), 1.75h, 4h, 6h, 8h, 12h, 24, 36h, 48h, 72h, 168h, 336h, 504 h after volasertib administration on Day 1 of Cycle 1 (Volasertib+ Itraconazole) and of Cycle 2 (Volasertib).
Secondary	Area Under the Plasma Concentration-time Curve Over the Time Interval From 0 to Infinity (AUC0-8) of Volasertib and Its Metabolite CD 10899	Area under the plasma concentration-time curve over the time interval from 0 to infinity (AUC0-8) of volasertib and its metabolite CD 10899 is reported.	30 minutes before volasertib administration and 1 hour (h), 1.75h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 168h, 336h, 504 h after volasertib administration on Day 1 of Cycle 1 (Volasertib+ Itraconazole) and of Cycle 2 (Volasertib).

External Links

•   Related Info